E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 3/17/2016 in the Prospect News PIPE Daily.

Bio Blast Pharma plans $6.7 million registered direct stock offering

Deal sells stock, warrants via Roth Capital Partners, Rodman & Renshaw

By Devika Patel

Knoxville, Tenn., March 17 – Bio Blast Pharma Ltd. said it will raise about $6.7 million in a registered direct offering of stock. Roth Capital Partners and Rodman & Renshaw are the agents.

The company will sell about 2.16 million ordinary shares. The purchase price, of $3.10 per share, reflects a 24.02% discount to the $4.08 closing share price on March 16.

Investors also will receive 66-month warrants for about 1.08 million shares, each exercisable at $4.50, which is a 10.29% premium to the March 16 closing share price.

Settlement is expected March 22.

The biopharmaceutical company is based in Tel Aviv.

Issuer:Bio Blast Pharma Ltd.
Issue:Ordinary stock
Amount:$6.7 million (approximate)
Shares:2.16 million (approximate)
Price:$3.10
Warrants:For about 1.08 million shares
Warrant expiration:66 months
Warrant strike price:$4.50
Agents:Roth Capital Partners and Rodman & Renshaw
Pricing date:March 17
Settlement date:March 22
Stock symbol:Nasdaq: ORPN
Stock price:$4.08 at close March 16
Market capitalization:$41.84 million

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.